nephrology

FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemia

https://pharmaphorum.com/news/fda-adcomm-turns-down-fibrogen-azs-roxadustat-for-ckd-anaemia/

Sanofi’s venglustat bombs again, but isn’t dead yet

https://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/

Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

https://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/

AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDA

https://pharmaphorum.com/news/astrazenecas-farxiga-gets-first-kidney-disease-ok-from-fda/

FDA sets September review date for Calliditas’ rare kidney disease drug

https://pharmaphorum.com/news/fda-sets-september-review-date-for-calliditas-rare-kidney-disease-drug/

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

https://pharmaphorum.com/news/calliditas-eyes-2022-approval-in-eu-for-rare-kidney-disease-drug-nefecon/

Alnylam files its third RNAi drug lumasiran in rare kidney disease

https://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/

3rd Chronic Kidney Disease Drug Development (CKD3) Summit

https://pharmaphorum.com/events/3rd-chronic-kidney-disease-drug-development-ckd3-summit-2/

3rd Chronic Kidney Disease Drug Development (CKD3) Summit

https://pharmaphorum.com/events/3rd-chronic-kidney-disease-drug-development-ckd3-summit/

1 2

Close in 10 seconds

Pharmaphorum.com

Search